4Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein Ⅱb/Ⅲa receptors. In: Sasahara AA, Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. New York, NY: Marcel Dekker, 1997. 355-65. 被引量：1
5The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty. N Engl J Med, 1994, 330 (14) : 956. 被引量：1
6Topol EJ,Califf RM,Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet Ⅱb/Ⅲa integrin for reduction of clinical restenosis: results at six months. Lancet, 1994,343(8902) :881. 被引量：1
7Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA,1997,278(6) :479. 被引量：1
8The EPILOG Investigators. Platelet glycoprotein Ⅱb/Ⅲa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med, 1997, 336(24) : 1689. 被引量：1
9The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refactory unstable angina: the CAPTURE Study. Lancet, 1997, 349(9062) : 1429. 被引量：1
10The IMPACT- Ⅱ Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT- Ⅱ. Lancet, 1997,349(9062) : 1422. 被引量：1
3Califf RM, Pursuit R. Presented at the 70th Scientific Sessions of the American Heart Association, 1997,11 : 7-12. 被引量：1
4The PRISM investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med, 1998,338:1498. 被引量：1
5Gurbel PA, Bilden KP, Zaman KA, et al. Clopidegrel loading with eptifibatide to arrest the reactivity of the Clopidogrel loading with Eptifibatide to Arrest the Reactivity of platelets ( CLEARP LATE LETS) study. Circulation, 2005,111:1153. 被引量：1
6Harrington RA, Pardigm. Presented at the 69th Scientific Sessions of the American Heart Association, 1996,11 : 10-13. 被引量：1
7Gowda RM, Khan IA, Vasvada BC, et al. Therapeutics of platelet glycoprorein Ⅱb/Ⅲa a receptor antagonism. Am J Ther, 2004,11 : 302-307. 被引量：1
8Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab reduce risk of unplanned coronary stent deployment: EPILOG trial results. Circulation, 1997,96:1-163. 被引量：1
9Topol E J, Ferguson JJ, Wersman HF, et al. Long-term protection from myocardial ischemic events in randomized trial of brief intergrin 133 blockade with percutaneous coronary intervention. JAMA, 1997,278:479. 被引量：1
10Jeong JH, Chun KJ, Park YH, et al. Safety of tirofiban therapy in korean patients with actute coronary syndrome. Circ J, 2005, 69 : 650-653. 被引量：1
